Canada

Patented medicine sales rose 10.6% to $24.4B

Canada’s annual price review found patented products accounted for 48 per cent of all medicine sales in 2025.

Sales of patented medicines in Canada reached $24.4 billion in 2025, up 10.6 per cent from the year before.

The Patented Medicine Prices Review Board’s annual report says patented products accounted for 48 per cent of sales across all medicines. Per-person sales rose to $588.08.

The board received reports covering 1,086 patented medicine dosage forms and strengths, including 82 new forms and strengths introduced during the year.

Canadian list prices ranked third highest among the board’s 11 comparison countries and seventh among 35 OECD countries. The figures use list prices before confidential rebates or discounts.

Rights holders reported $1.73 billion in Canadian research and development spending, a 33.9 per cent increase. The research-to-sales ratio rose from 3.7 to 4.9 per cent.

Source

News brief based on the linked federal report.